comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice GLP-1 receptor agonists, including semaglutide
Description
This dual action on both glycemic control and cardiovascular health has elevated GLP-1 receptor agonists to an important position in diabetes management
2% WL with placebo in people with obesity [68]
The product also carries an FDA boxed warning regarding thyroid C-cell tumors
Patients should be incredibly careful about where their treatment is coming from to ensure they are receiving safe, regulated medication
R., Obesity and Prognosis of Breast Cancer, Obesity Reviews 7 (2006): 333340
